Table 2.
Immunoreactivity of selected epithelial and stromal markers of paired primary tumor and metastasis biopsies, sampled with a median time of 1.9 years in-between.
| Primary Tumor | Metastases | RS (n) | |
|---|---|---|---|
| Epithelial markers | |||
| ERG (pos./total) Epithelial markers | 30/80 | 21/80 ** | 0.71 *** |
| Ki67 (%), n = 98 | 13 (7.5; 20) | 16 (9.3; 25) * | 0.38 *** |
| PSA (score), n = 98 | 8 (6; 12) | 6 (4; 9) * | 0.37 *** |
| AR (score), n = 92 | 12 (8; 12) | 8 (4; 12) *** | 0.22 * |
| Stromal markers | |||
| Ki67 (%), n = 75 | 1.5 (0.95; 2.9) | 5.0 (3.0; 7.0) *** | 0.074 |
| AR (%), n = 68 | 19 (13; 28) | 2.7 (1.5; 4.0) *** | 0.27 * |
| SMA density (%), n = 50 | 16 (12; 18) | 5.3 (3.5; 8.3) *** | 0.097 |
| SDF-1 density (%), n = 51 | 3.1 (2.1; 4.1) | 4.3 (3.4; 6.1) *** | −0.27 |
| PDGFRβ density (%), n = 37 | 9.1 (5.0; 13) | 10 (8.3; 13) * | 0.26 |
| ERG, endothelium density (%), n = 69 | 1.0 (0.66; 1.5) | 1.0 (0.62; 1.4) | 0.44 |
Marker values are median and 25th and 75th percentiles, * p < 0.05, ** p < 0.01, *** p < 0.001. ERG, ETS-related gene; Ki67, marker for proliferation; PSA, prostate specific antigen; AR, androgen receptor; SMA, smooth muscle actin; SDF-1, stroma derived factor 1; PDGFRβ, platelet-derived growth factor receptor β.